159 related articles for article (PubMed ID: 33225828)
1. The Joint i3+3 (Ji3+3) design for phase I/II adoptive cell therapy clinical trials.
Lin X; Ji Y
J Biopharm Stat; 2020 Nov; 30(6):993-1005. PubMed ID: 33225828
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials.
Li DH; Whitmore JB; Guo W; Ji Y
Clin Cancer Res; 2017 Jan; 23(1):13-20. PubMed ID: 27742793
[TBL] [Abstract][Full Text] [Related]
3. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology.
Lin X; Ji Y
Stat Methods Med Res; 2021 Mar; 30(3):843-856. PubMed ID: 33327870
[TBL] [Abstract][Full Text] [Related]
4. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
5. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
6. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials.
Lin R; Yin G; Shi H
Biostatistics; 2023 Apr; 24(2):277-294. PubMed ID: 34296266
[TBL] [Abstract][Full Text] [Related]
7. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
Li P; Liu R; Lin J; Ji Y
J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
[TBL] [Abstract][Full Text] [Related]
8. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
9. Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
Zang Y; Lee JJ; Yuan Y
Clin Trials; 2014 Jun; 11(3):319-327. PubMed ID: 24844841
[TBL] [Abstract][Full Text] [Related]
10. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
11. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
12. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.
Sato H; Hirakawa A; Hamada C
Stat Med; 2016 Oct; 35(23):4093-109. PubMed ID: 27221807
[TBL] [Abstract][Full Text] [Related]
13. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.
Mu R; Hu Z; Xu G; Pan H
BMC Med Res Methodol; 2021 Dec; 21(1):278. PubMed ID: 34895153
[TBL] [Abstract][Full Text] [Related]
14. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
15. The i3+3 design for phase I clinical trials.
Liu M; Wang SJ; Ji Y
J Biopharm Stat; 2020 Mar; 30(2):294-304. PubMed ID: 31304864
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding based on feasibility and late-onset toxicity in adoptive cell therapy trials.
Bagley EM; Wages NA
J Biopharm Stat; 2024 Mar; 34(2):151-163. PubMed ID: 36879525
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
18. Phase I CAR-T Clinical Trials Review.
Bulsara S; Wu M; Wang T
Anticancer Res; 2022 Dec; 42(12):5673-5684. PubMed ID: 36456127
[TBL] [Abstract][Full Text] [Related]
19. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
20. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
Takahashi A; Suzuki T
Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]